PMID- 31899963
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 2169-141X (Electronic)
IS  - 2169-1401 (Linking)
VI  - 48
IP  - 1
DP  - 2020 Dec
TI  - Prognostic and clinicopathologic significance of long non-coding RNA 
      opa-interacting protein 5-antisense RNA 1 in multiple human cancers.
PG  - 353-361
LID - 10.1080/21691401.2019.1709854 [doi]
AB  - Background: OIP5-AS1 has been reported to be aberrantly expressed in multiple 
      cancers and associated with clinical outcomes. We conducted this study to assess 
      the generalized prognostic value of OIP5-AS1 in cancers.Methods: PubMed, Web of 
      science, and Cochrane Library were searched for eligible studies. Hazards ratios 
      (HRs) or odd ratios (ORs) with 95% confidence intervals (CIs) were pooled to 
      estimate the prognostic value of OIP5-AS1 in cancers, including overall survival 
      (OS), age, gender, tumor size, clinical stage, and lymph node metastasis (LNM). 
      Publication bias was measured by Begg's test and funnel plot. Sensitivity 
      analysis were used to detect the stability of pooled results.Results: Overall, 
      eleven studies containing 713 patients were eventually enrolled. The pooled 
      results showed that high OIP5-AS1 expression was correlated with shorter OS 
      (HR = 0.48, 95%CI: 0.35-0.64), regardless of the sample size, tumor type and 
      follow-up time. Furthermore, elevated expression of OIP5-AS1 indicated advanced 
      clinical stage (OR = 2.12, 95% CI: 1.06-4.23), but not associated with age, 
      gender, tumor size and LNM. No publication bias was detected.Conclusion: High 
      expression of lncRNA OIP5-AS1 may predict a poor OS and advanced clinical stage, 
      implicating that OIP5-AS1 may be a possible prognostic factor in cancers.
FAU - Ren, Xiaolei
AU  - Ren X
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
FAU - He, Jieyu
AU  - He J
AD  - Department of Geriatrics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
FAU - Qi, Lin
AU  - Qi L
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
FAU - Li, Shuangqing
AU  - Li S
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
FAU - Zhang, Chenghao
AU  - Zhang C
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
FAU - Duan, Zhixi
AU  - Duan Z
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
FAU - Wang, Wanchun
AU  - Wang W
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
AD  - Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second 
      Xiangya Hospital, Central South University, Changsha, People's Republic of China.
FAU - Tu, Chao
AU  - Tu C
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
AD  - Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second 
      Xiangya Hospital, Central South University, Changsha, People's Republic of China.
FAU - Li, Zhihong
AU  - Li Z
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, People's Republic of China.
AD  - Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second 
      Xiangya Hospital, Central South University, Changsha, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PT  - Video-Audio Media
PL  - England
TA  - Artif Cells Nanomed Biotechnol
JT  - Artificial cells, nanomedicine, and biotechnology
JID - 101594777
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (long noncoding RNA OIP5, human)
SB  - IM
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Neoplasm Staging
MH  - *Neoplasms/metabolism/mortality/pathology
MH  - RNA, Long Noncoding/*biosynthesis
MH  - RNA, Neoplasm/*biosynthesis
MH  - Survival Rate
OTO - NOTNLM
OT  - LncRNA
OT  - OIP5-AS1
OT  - biomarker
OT  - cancer
OT  - osteosarcoma
EDAT- 2020/01/05 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/01/05 06:00
PHST- 2020/01/05 06:00 [entrez]
PHST- 2020/01/05 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1080/21691401.2019.1709854 [doi]
PST - ppublish
SO  - Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):353-361. doi: 
      10.1080/21691401.2019.1709854.